DelveInsight’s “Nonalcoholic Steatohepatitis Market Insight, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of Nonalcoholic Steatohepatitis, historical and forecasted epidemiology as well as the Nonalcoholic Steatohepatitis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Unlock detailed insights into the Nonalcoholic Steatohepatitis Market @ Nonalcoholic Steatohepatitis Therapeutics Market
Key Takeaways from the Nonalcoholic Steatohepatitis Market Report
- Based on DelveInsight’s estimates, the United States had the highest number of Nonalcoholic Steatohepatitis Diagnosed Prevalence Cases in 2023, with a total of ~9.4 million cases. Following the US, EU4 and the UK had ~3.6 million cases, while Japan had ~2.5 million cases.
- The categorization based on gender, showed that Nonalcoholic Steatohepatitis diagnosed prevalent cases in males were higher than in females in the 7MM. The male-diagnosed prevalent cases accounted for 56% of the total cases in the 7MM.
- Japan accounted for approximately 16% of the total NASH Diagnosed Prevalent Cases in the 7MM in 2023. These cases are expected to increase in the study period (2020–2034).
- The leading Nonalcoholic Steatohepatitis Companies such as Madrigal Pharmaceuticals, Novo Nordisk A/S, 89bio, Inc., Akero Therapeutics, Inc., Galectin Therapeutics, Sagimet Biosciences, Inventiva Pharma and others.
- Promising Nonalcoholic Steatohepatitis Therapies such as REZDIFFRA (resmetirom), Pegozafermin (BIO89-100), Efruxifermin (EFX), Belapectin, Semaglutide, Denifanstat and others.
Visit our website to access the full report and make informed strategic decisions @ Nonalcoholic Steatohepatitis Treatment Drugs
Nonalcoholic Steatohepatitis Epidemiology Segmentation in the 7MM
- Total Nonalcoholic Steatohepatitis Prevalence Cases
- Total Nonalcoholic Steatohepatitis Diagnosed Prevalence Cases
- Nonalcoholic Steatohepatitis Gender-specific Diagnosed Prevalence Cases
- Nonalcoholic Steatohepatitis Severity-specific Diagnosed Prevalence Cases
Download the report to understand which factors are driving Nonalcoholic Steatohepatitis Epidemiology Trends @ Nonalcoholic Steatohepatitis Prevalence
Marketed Nonalcoholic Steatohepatitis Drugs
- REZDIFFRA (resmetirom): Madrigal Pharmaceuticals
REZDIFFRA is indicated in conjunction with diet and exercise for the treatment of adults with noncirrhotic NASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis). The emergence of the inaugural medication for NASH is a true game-changer for healthcare providers, the research community, and, most importantly, patients living with this serious liver condition. Based on the robust efficacy and safety data generated in two large Phase III MAESTRO studies, it is believed that REZDIFFRA will become the foundational therapy for patients with NASH with moderate to advanced liver fibrosis. As well as since now that the FDA has approved REZDIFFRA for NASH, NASH Companies will have a better understanding of the thresholds they must meet to get future approvals.
Emerging Nonalcoholic Steatohepatitis Drugs
- Pegozafermin: 89bio, Inc
Pegozafermin or BIO89-100 is a compound that specifically targets and activates a receptor known as fibroblast growth factor 21 (FGF21). FGF21 is a hormone involved in regulating glucose and lipid metabolism, and it has been shown to have potential therapeutic effects in NASH. NASH Preclinical studies and early-stage clinical trials of BIO89-100 have shown promising results in improving metabolic parameters and reducing liver fat accumulation in patients with NASH.
- Efruxifermin (EFX): Akero Therapeutics, Inc.
Efruxifermin (EFX), is Akero’s lead product candidate for NASH. It is a differentiated Fc-FGF21 fusion protein engineered to mimic the balanced biological activity profile of native FGF21, an endogenous hormone that alleviates cellular stress and regulates metabolism throughout the body. EFX is designed to offer convenient once-weekly SC dosing. The consistency and magnitude of observed effects position EFX to be a potentially best-in-class medicine, if approved, for treating NASH.
- Belapectin: Galectin Therapeutics
Belapectin a complex carbohydrate drug, targets galectin-3, a critical protein in fatty liver disease and fibrosis pathogenesis. Galectin-3 plays a major role in organ scarring diseases, including the liver, lung, kidney, heart, and vascular systems fibrotic disorders. The drug binds to galectin-3 proteins and disrupts its function.
Discover key developments and opportunities in the Nonalcoholic Steatohepatitis Market @ Nonalcoholic Steatohepatitis Market Size
Nonalcoholic Steatohepatitis Market Insights
the advent of REZDIFFRA marks a significant breakthrough in NASH treatment, offering hope and promise to millions affected by this complex liver condition. As the pioneering FDA-approved therapy for NASH, REZDIFFRA leads innovation, transforming treatment. While other emerging therapies such as lanifibranor, VK2809, Semaglutide, and others show promise in addressing NASH, REZDIFFRA’s unique efficacy and safety profile position it as the cornerstone of NASH management. As we navigate this dynamic era of medical advancement, REZDIFFRA stands as a guiding light, illuminating the path toward a future where effective treatment and improved outcomes are within reach for all those affected by NASH.
Nonalcoholic Steatohepatitis Companies
Madrigal Pharmaceuticals, Novo Nordisk A/S, 89bio, Inc., Akero Therapeutics, Inc., Galectin Therapeutics, Sagimet Biosciences, Inventiva Pharma and others.
Nonalcoholic Steatohepatitis Market Outlook
Until mid-March, the Nonalcoholic Steatohepatitis Therapeutics Market Landscape lacked FDA, EMA, or PMDA-approved medications, relying primarily on lifestyle adjustments like diet and exercise. Supplemental interventions encompassed off-label usage of vitamin E and antidiabetic agents (e.g., pioglitazone, liraglutide) and liver transplantation in case of severe stages. Given NASH’s multifaceted pathogenesis, effective treatment demands comprehensive targeting of various cellular and molecular pathways.
Download DelveInsight’s Nonalcoholic Steatohepatitis Market report today @ Nonalcoholic Steatohepatitis Clinical Trials
Scope of the Nonalcoholic Steatohepatitis Market Report
- Coverage- 7MM
- Study Period- 2020-2034
- Nonalcoholic Steatohepatitis Companies- Madrigal Pharmaceuticals, Novo Nordisk A/S, 89bio, Inc., Akero Therapeutics, Inc., Galectin Therapeutics, Sagimet Biosciences, Inventiva Pharma and others.
- Nonalcoholic Steatohepatitis Therapies-REZDIFFRA (resmetirom), Pegozafermin (BIO89-100), Efruxifermin (EFX), Belapectin, Semaglutide, Denifanstat and others.
- Nonalcoholic Steatohepatitis Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Nonalcoholic Steatohepatitis Unmet Needs, KOL’s views, Analyst’s views, Nonalcoholic Steatohepatitis Market Access and Reimbursement
Table of Contents
- Key Insights
- Nonalcoholic Steatohepatitis Market Report Introduction
- Country-wise Nonalcoholic Steatohepatitis Market Overview at a Glance
- Nonalcoholic Steatohepatitis Market Overview by Therapeutic Class
- Methodology of Nonalcoholic Steatohepatitis Epidemiology and Market
- Nonalcoholic Steatohepatitis Executive Summary
- Key Events
- Nonalcoholic Steatohepatitis Disease Background and Overview
- Nonalcoholic Steatohepatitis Epidemiology and Patient Population
- Nonalcoholic Steatohepatitis Patient Journey
- Nonalcoholic Steatohepatitis Marketed Drugs
- Nonalcoholic Steatohepatitis Emerging Drugs
- Nonalcoholic Steatohepatitis: Market Analysis
- Key Opinion Leaders’ Views
- Nonalcoholic Steatohepatitis SWOT Analysis
- Nonalcoholic Steatohepatitis Unmet Needs
- Nonalcoholic Steatohepatitis Market Access and Reimbursement
- Appendix
- Nonalcoholic Steatohepatitis Report Methodology
- DelveInsight Capabilities
- Disclaimer
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
